



Sociedad Española
de Reumatología -
Colegio Mexicano
de Reumatología

Reumatología Clínica

www.reumatologiaclinica.org



Original Article

Cost evolution of biological drugs in rheumatoid arthritis patients in a tertiary hospital: Influential factors on price



Mariángeles González Fernández^{a,*}, Elena Villamañán^b, Inmaculada Jiménez-Nácher^b, Francisco Moreno^b, Chamaida Plasencia^c, Francisco Gayá^d, Alicia Herrero^b, Alejandro Balsa^c

^a Pharmacy Department, La Paz University Hospital, Paseo de la Castellana 261, 28046 Madrid, Spain

^b Pharmacy Department, La Paz University Hospital, Madrid, Spain

^c Rheumatology Department, La Paz University Hospital, Madrid, Spain

^d Biostatistic Department, La Paz University Hospital, Madrid, Spain

ARTICLE INFO

Article history:

Received 14 May 2019

Accepted 16 October 2019

Available online 24 December 2019

Keywords:

Cost
Arthritis
Rheumatoid
Optimization
Therapy

ABSTRACT

Objective: To assess the evolution of cost per patient/year and the cost per patient/year/drug in patients with rheumatoid arthritis (RA) receiving biological treatments. To analyze and quantify the factors influencing this evolution, such as the optimization of the biological drugs, the use of biosimilars, and official discounts and discounts obtained after negotiated procedures. In addition, to assess specific clinical parameters of disease activity in these patients.

Methods: Retrospective, observational study conducted in a Spanish tertiary hospital. Adult patients diagnosed with RA under treatment from 2009 to 2017 were included.

Results: 320, 270 and 389 patients were included in 2009, 2013 and 2017, respectively. The patient/year cost decreased from 10,789€ in 2009, 7491€ in 2013 to 7116€ in 2017. In 2017, due to the established competition, discounts of 14% and 29.5% were achieved on etanercept and its biosimilar; 11.5%, 17.8%, 17.9%, 17.3% on adalimumab, certolizumab, golimumab and tocilizumab IV respectively, and 24.6% and 43.1% on infliximab and its biosimilar. The percentage of patients optimized in 2017 was 35.2%. The annual saving in 2017 was 1,288,535€ (830,000€ due to dose optimization and/or administration regimens, 249,666€ corresponding to 7.5% of the official discount and 208,868€ after negotiated procedures).

Conclusion: The annual cost per patient in RA decreased considerably due to different factors, such as discounts on the purchase of drugs due to official discounts and negotiated procedures, together with the optimization of therapies, the latter being the factor that contributed most to this decrease.

© 2019 Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología. All rights reserved.

Evolución del coste de medicamentos biológicos en pacientes con artritis reumatoide en un hospital terciario. Factores influyentes en dicha evolución

RESUMEN

Objetivo: Evaluar la evolución del coste por paciente/año y del coste por paciente/año/medicamento en pacientes en tratamientos con biológicos con artritis reumatoide (AR). Analizar y cuantificar los factores influyentes en dicha evolución tales como la optimización de medicamentos biológicos, el uso de biosimilares y los descuentos oficiales y los obtenidos tras procedimientos negociados. Además, evaluar parámetros clínicos de la actividad propios de la enfermedad en dichos pacientes.

Métodos: Estudio retrospectivo, observacional, realizado en un hospital terciario español. Se incluyeron pacientes adultos diagnosticados de AR en tratamiento con biológicos desde 2009 a 2017.

Palabras clave:

Coste
Artritis
Reumatoide
Optimización
Terapia

* Corresponding author.

E-mail address: magonzalez.hulp@salud.madrid.org (M. González Fernández).

Resultados: Se incluyeron 320, 270 y 389 pacientes en 2009, 2013 y 2017, respectivamente. El coste paciente/año disminuyó de 10.798€ en 2009, 7.491€ en 2013 a 7.116€ en 2017. En 2017, debido a la competencia establecida, se alcanzaron descuentos del 14 y del 29,5% en etanercept y su biosimilar; 11,5, 17,8, 17,9 y 17,3% en adalimumab, certolizumab, golimumab y tocilizumab IV, respectivamente, así como un 24,6% y 43,1% en infliximab y su biosimilar. El porcentaje de pacientes optimizados en 2017 alcanzó el 35,2%. El ahorro anual en 2017 fue de 1.288.535€ (830.000€ debido a la optimización de dosis y/o pautas de administración, 249.666€ correspondiente al 7,5% del descuento oficial y 208.868€ tras procedimientos negociados).

Conclusión: El coste anual por paciente en AR disminuyó considerablemente debido a diferentes factores, tales como, descuentos en la adquisición de medicamentos debido a descuentos oficiales y procedimientos negociados, junto a la optimización de terapias, siendo este último el factor que más contribuyó en dicho descenso.

© 2019 Elsevier España, S.L.U.

y Sociedad Española de Reumatología y Colegio Mexicano de Reumatología. Todos los derechos reservados.

Introduction

Rheumatoid arthritis (RA) is a chronic, progressive auto immune disease that causes severe articular damage and functional impotence in the affected joints.¹ The prevalence of RA is reported to be 0.5%–1% in developed countries, with a higher prevalence among females (ratio 2:1).^{1,2} Its prevalence is 0.5% in Spain.³ The therapy of RA aims at early disease control and induction of sustained remission; successful treatment is reflected by sustained quality of life and ability to work.⁴

Treatment with nonsteroidal anti-inflammatory drugs, conventional disease-modifying antirheumatic drugs and biologic treatment have been assessed in individuals with RA.⁵ Biologics drugs (BD) approved for use in RA include TNF inhibitors (TNFi), Tocilizumab (Tcz), Rituximab (Rtx), Abatacept (Aba) and Janus kinase inhibitors tofacitinib and baricitinib (Jak).^{6–8} The TNFi registered for the indication of RA are adalimumab (Ada), certolizumab pegol (Ctz), etanercept (Etn), golimumab (Goli), and infliximab (Ifx).^{5,7,9} TNFi have improved outcomes for patients who are refractory or intolerant to conventional treatments, inducing long-term remission in some cases.^{10,11} If TNFi fails, switching to another TNFi or an agent with another mode of action should be considered.^{6–9} The cost of BD for treating rheumatic diseases has dramatically increased in Spanish hospitals.¹² Due to the high cost of BD, it is important to evaluate real costs of use of these agents.¹³

Aims of the study

The main objective was to calculate the annual cost per patient and the cost of each biological treatment of patients with RA in real practice in a tertiary hospital in Spain for eighteen years (2009–2017). Other secondary objectives were to analyze factors related to treatment costs (the prescription of biosimilars instead of original drugs, discounts and negotiated rebates or biologic regimes optimization according to drug and anti-drug antibodies serum levels.^{14–16}

Methods

We conducted a retrospective observational study between 2009 and 2017 approved by Ethics Committee of La Paz University hospital in April 2017.

Patients diagnosed of RA who were dispensed BD by the pharmacy department in the study period were included. These dispensations were recorded in a CPOE program (FarmaTools 2.5 Dominion). This software allows pharmacists to register regimes, drugs and unit-drugs used by patient and related them with costs.

Inclusion criteria

Adult patients with RA followed in the rheumatology unit in our hospital were included.

Clinical data were obtained from the La Paz Biological Registry of Rheumatology database, created by the hospital's rheumatology department. Disease activity was measured by the Disease Activity Score 28 (DAS28) and the Simplified Disease Activity Index (SDAI).¹⁷ Remission was defined as achieving a DAS28 < 2.6 and SDAI ≤ 3; low disease activity were defined as ≥ 2.6 DAS28 < 3.2, and > 3.3 SDAI ≤ 11; moderate activity were defined as ≥ 3.2 DAS28 < 5.1, and > 11 SDAI ≤ 26; and high activity were defined as DAS28 > 5.1 and SDAI > 26.^{6,17} These parameters, as well as C-reactive protein (C-RP) and erythrocyte sedimentation rate, were measured every 3–6 months for clinical disease assessment.

Costs were calculated according to direct cost of BD dispensed. Drugs prices used were those set out by the Spanish Medicines Agency.¹⁸ Costs associated with concomitant medications, laboratory tests or a switch from initial therapy that affected the overall cost were excluded.

Main variables and secondary variables

To calculate main outcomes such as *average-dispensed-patient*, *the annual cost per average-patient* and *annual cost per average-patient per drug* we applied a standardized methodology used by the public health system of the Community of Madrid. In addition, other variables such the *theoretical cost per drug (units) acquired*, *annual theoretical cost per drug*, *total cost savings* and *the cost savings as a result of biological therapy optimization* were calculated.^{15,16}

Biological therapy optimization by monitoring drug and ADA serum levels

We also evaluated annual costs per patient and per drug savings due to biologic therapies optimization. Optimized therapies were defined as those in which the dosing interval were extended and/or the dose of biological drug was reduced. Total percentages of patients with optimized therapies and per drug were calculated.

Statistical analysis

The results were expressed as percentage, mean and standard deviation (SD). All tests were performed using IBM SPSS version 19.0. Differences in patients' characteristics were examined using the analysis of variance (ANOVA) model or a t-test for continuous variables (age, DAS28, SDAI, C-RP, ESR). Differences in costs were

Table 1
Characteristics of patients.

	2009	2013	2017	P(*) (between groups)
Dispensed patient	320	270	389	
Ages (years)	56.94 (14.51)	57.87 (13.25)	58.20 (14.72)	.562 (NS)
Gender (female)	236 (73.75%)	218 (80.74%)	321 (85.55%)	
DAS28	3.57 (1.35)	3.31 (1.25)	3.21 (1.29)	.012 (S)
SDAI	11.86 (11.85)	10.93 (11.13)	9.97 (9.55)	.303 (NS)
CRP-C	5.69 (9.09)	6.51 (13.62)	6.39 (12.89)	.366 (NS)
ESR	22.09 (15.92)	18.93 (13.28)	21.18 (16.17)	.086 (NS)

Data are expressed as mean (SD) for continuous variables and frequencies (percentage) for categorical variables

DAS28: Disease Activity Score28; SDAI: Simplified Disease Activity Index.

CRP-C: C-Reactive Protein; ESR Erythrocyte Sedimentation Rate.

Statistical signification $P < .05$; (*) ANOVA test.




Fig. 1. Data evolution in rheumatoid arthritis from 2009 to 2017. (a) Average dispensed patient from 2009 to 2017. (b) Annual cost for rheumatoid arthritis 2009–2017. (c) Annual cost 2017 per average dispensed patient 2009–2017.

examined using analysis of trends (Joinpoint Regression Program® 4.5.01-June, 2017). Significant values were defined as $P < .05$.

Results

In 2009, 2013, and 2017 were treated with BD 320, 270, and 389 patients respectively. Patient’s characteristics are shown in Table 1. No statistically significant difference was found between study groups except in DAS28.

Fig. 1 shows the evolution of the results for RA per average-dispensed-patient, annual cost, and annual cost per average-dispensed-patient. “We observed an average-dispensed-patient decrease from 2009 to 2013, and an upward trend from 2014 to 2017 (Fig. 1a)”. The same tendency in terms of annual cost of RA was observed, with a minimum data in 2013 (Fig. 1b)”. However, the annual cost per patient decreased ($P < .001$ from 2009 to 2013) (Fig. 1c).

When evaluating costs according to each drug used a similar trend was observed (Table 2). Annual cost per patient from 2009 to 2017 decreased significantly for Ixf and Eta ($P < .001$), Ctz and Aba IV ($P < .05$), and from 2009 to 2013 for Ada ($< .001$) and Toci IV ($P < .05$).

Biologics acquired by our center (units) as well as the data for BD dispensed (units) to patients with RA are shown in Table 3. We detected that there was an increase in the number of marketed BD and total savings per drug. In order of appearance, official discounts and negotiated rebates in 2017 were 11.5% for Ada, 15.5% for Eta,

30.9% for Ixf, 17.9% for Goli, 17.8 for Ctz and 17.4% for Rtx, and 19.8% for Aba SC, 15.9% for Tcz, 10.3% for Bari and 7.5% for Tofa, the latest released biological. We checked that the release of a biosimilar infliximab increased the rebates up to 43.1% in 2017, with a gradual increase in bonus units over time while original Ixf rebate reached a 24.6%.

Disease activity decreased annually in patients with optimized regimes when compared with patients without optimized regimes ($P < .001$) (Table 4a).

As Fig. 2 shows, active patients and percentage using optimized regimes from 2009 to 2017, reached 51.5% and 35.2% of patients with optimization by 2013 and 2017 respectively. The optimized therapies per drug and annually was analyzed (Table 4b).

Costs evolution according to the factors studied (results in 2017 are shown in Table 5). Thus, costs savings related to therapy optimization (830,000€), costs savings by monitoring drug and anti-drug antibody (ADA) serum levels in 2017 represented a 73.87% (613,101€).

Moreover, costs savings by drugs monitoring were 88.08% (322,882€) in 2011, 75.38% (797,906€) in 2013 and a 79.19% (730,810€) in 2015.

Moreover, we found that from 2009 to 2017 the total savings increased (Table 6). The greatest contribution to economic savings was therapy optimization (24.93%). Savings associated with official discounts and negotiated rebates (13.77%) in 2017 (Table 6).

Table 2
Economic data evolution per drug from 2009 to 2017 in rheumatoid arthritis.

	2009	2010	2011	2012	2013	2014	2015	2016	2017
<i>Adalimumab</i>									
Average dispensed patient	62.12	59.91	59	52.7	41.54	35.52	35.17	34.24	30.73
Annual cost (€)	781.698	722.026	596.887	488.699	301.058	239.691	245.295	233.874	215.512
Annual cost per average patient (€)	12.584	12.052	10.117	9.273	7.247	6.748	6.975	6.830	7.013
Incremental difference annual cost									
<i>Etanercept</i>									
Average dispensed patient	73.58	68.58	66.53	70.44	73.48	69.92	70.46	78.91	86.16
Annual cost (€)	802.414	737.450	660.645	633.196	543.150	556.287	554.835	549.650	579.680
Annual cost per average patient (€)	10.905	10.753	9.930	8.989	7.392	7.956	7.874	6.966	6.728
Incremental difference annual cost		−1.4%	−7.7%	−9.5%	−17.8%	7.6%	−1.0%	−11.5%	−3.4%
<i>Certolizumab</i>									
Average dispensed patient	–	0.5	8.6	17.95	22.23	24.75	33	37.53	44.48
Annual cost (€)	–	4.260	87.869	172.010	178.747	194.765	246.084	281.660	335.283
Annual cost per average patient (€)	–	8.520	10.217	9.583	8.041	7.869	7.457	7.505	7.538
Incremental difference annual cost				−6.2%	−16.1%	−2.1%	−5.2%	0.6%	0.4%
<i>Golimumab</i>									
Average dispensed patient	–	–	1.83	1	1.41	3.9	4.6	9.16	11.38
Annual cost (€)	–	–	14.521	9.564	14.573	33.965	37.326	85.081	96.171
Annual cost per average patient (€)	–	–	7.935	9.564	10.335	8.709	8.114	9.288	8.451
Incremental difference annual cost					8.1%	−15.7%	−6.8%	14.5%	−9.0%
<i>Infliximab</i>									
Average dispensed patient	64.54	47.83	37.72	31.6	22.78	25.29	29.98	24.09	27.68
Annual cost (€)	628.903	439.037	283.243	187.865	123.575	142.822	188.394	103.430	92.414
Annual cost per average patient (€)	9.744	9.179	7.509	5.945	5.425	5.647	6.284	4.293	3.339
Incremental difference annual cost		−5.8%	−18.2%	−20.8%	−8.7%	4.1%	11.3%	−31.7%	−22.2%
<i>Tocilizumab IV</i>									
Average dispensed patient	–	3.87	10.66	16.2	23.79	27.17	25.35	17.52	20.92
Annual cost (€)	–	46.437	118.381	167.048	199.503	210.997	185.996	121.669	158.076
Annual cost per average patient (€)	–	11.999	11.105	10.312	8.386	7.766	7.337	6.945	7.556
Incremental difference annual cost			−7.5%	−7.1%	−18.7%	−7.4%	−5.5%	−5.3%	8.8%
<i>Tocilizumab SC</i>									
Average dispensed patient	–	–	–	–	–	–	9.38	20.91	28.9
Annual cost (€)	–	–	–	–	–	–	68.410	154.759	240.921
Annual cost per average patient (€)	–	–	–	–	–	–	7.293	7.401	8.336
Incremental difference annual cost								1.5%	12.6%
<i>Abatacept IV</i>									
Average dispensed patient	7.16	4.6	7.08	8.93	7.95	7.81	8.5	8.46	10.21
Annual cost (€)	81.131	53.252	81.497	89.371	66.972	67.728	82.066	69.025	90.261
Annual cost per average patient (€)	11.331	11.577	11.511	10.008	8.424	8.672	9.655	8.159	8.840
Incremental difference annual cost		2.2%	−0.6%	−13.1%	−15.8%	2.9%	11.3%	−15.5%	8.3%
<i>Abatacept SC</i>									
Average dispensed patient	–	–	–	–	–	–	8.52	12.26	12.86
Annual cost (€)	–	–	–	–	–	–	80.151	99.619	102.692
Annual cost per average patient (€)	–	–	–	–	–	–	9.407	8.126	7.985
Incremental difference annual cost								−13.6%	−1.7%
<i>Rituximab</i>									
Average dispensed patient	24.4	21.99	15.67	15.43	14.98	23.58	21.54	29.71	29.51
Annual cost (€)	210.095	169.293	134.357	115.163	128.359	135.331	177.886	202.985	242.484
Annual cost per average patient (€)	8.610	7.699	8.574	7.464	8.569	5.739	8.258	6.833	8.217
Incremental difference annual cost		−10.6%	11.4%	−12.9%	14.8%	−33.0%	43.9%	−17.3%	20.3%
<i>Baricitinib VO</i>									
Average dispensed patient	–	–	–	–	–	–	–	–	0.33
Annual cost (€)	–	–	–	–	–	–	–	–	2.508
Annual cost per average patient (€)	–	–	–	–	–	–	–	–	7.600
<i>Tofacitinib VO</i>									
Average dispensed patient	–	–	–	–	–	–	–	–	0.42
Annual cost (€)	–	–	–	–	–	–	–	–	3.266
Annual cost per average patient (€)	–	–	–	–	–	–	–	–	7.776

Discussion

The results obtained are in line with an article that we recently published in patient with Spondyloarthritis.¹⁶ Over the study period there was a marked decrease in annual cost per-average-patient diagnosed with RA (incremental difference: −34.9%), however average-dispensed-patient trend increased. Also annual cost per drug decreased during 2009–2017.

In Spain, the Royal Decree Law 4/2010 implementation in June 2010 lead to decreased the prices of all medications by 7.5%¹⁹ this fact was associated with cost reduction from 2010 to 2011. Therapy optimization, use of biosimilar TNFi, and official discounts or negotiated rebates that lowered prices in some biologics were other factors associated to the cost reduction for 2011–2017.¹⁶

Different published studies have analyzed the economic impact of biological therapies in RA. Gómez-DeRueda et al.,²⁰ in a study

Table 3
Official discounts and negotiated rebates from 2009 to 2017.

	2009	2010	2011	2012	2013	2014	2015	2016	2017	
<i>Adalimumab</i>	<i>Total acquired</i>									
Rebates (€)	3.161	183,172	374,030	301,885	306,498	322,854	305,937	531,078	360,828	
Rebates (% Unit)	0.2%	6.7%	12.8%	11.1%	11.5%	12.1%	11.6%	16.7%	11.5%	
Bonus (U)	0	0	314	200	202	128	166	606	282	
Dispensed units (U) in RA	1.489	1.438	1.260	1.023	635	501	487	551	508	
Rebates in RA (€)	1.198	5.415	87,209	61,100	40,038	33,454	26,629	46,500	27,326	
<i>Etanercept</i>	<i>Total acquired</i>									
Rebates (€)	37,680	152,295	202,444	240,499	209,525	228,183	262,751	260,054	297,629	
Rebates (% Unit)	1.5%	6.1%	8.8%	10.3%	10.3%	10.6%	12.6%	12.4%	15.5%	
Bonus (U)	0	0	0	0	0	0	2,400	23,500	26,600	
Dispensed units (U) in RA	165,425	160,050	146,925	143,075	122,960	128,700	132,775	141,500	160,750	
Rebates in RA (€)	15,061	59,908	79,207	74,039	61,421	67,608	79,733	80,189	104,404	
<i>Infliximab</i>	<i>Total acquired</i>									
Rebates (€)	3.313	114,842	269,141	413,595	391,423	340,626	561,199	286,529	746,340	
Rebates (% Unit)	0.1%	4.8%	10.0%	13.4%	15.1%	12.7%	19.6%	11.7%	30.90%	
Bonus (U)	0	0	65	112	134	0	118	84	34	
Dispensed units (U) in RA	1.131	821	561	390	262	265	109	271	323	
Rebates in RA (€)	935	22,206	32,831	33.115	21.908	20.880	35.927	18.502	43.842	
<i>Golimumab</i>	<i>Total acquired</i>									
Rebates (€)		10,455	71,370	60,224	134,736	197,754	83,426	91,867	142,098	
Rebates (% Unit)		100.0%	37.0%	30.3%	25.8%	30.2%	17.7%	13.7%	17.90%	
Bonus (U)		0	50	14	0	13	7	0	43	
Dispensed units (U) in RA		9	25	12	21	39	47	107	127	
Rebates in RA (€)		10,455	13,024	3,950	6,373	14,662	7,953	14,205	20,119	
<i>Certolizumab</i>	<i>Total acquired</i>									
Rebates (€)		13,064	25,783	61,679	72,288	92,400	87,027	77,024.6	88,822	
Rebates (% Unit)		32.3%	22.9%	24.6%	26%	25.5%	21%	17.7%	17.80%	
Bonus (U)		10	0	0	0	0	40	0	0	
Dispensed units (U) in RA		14	240	462	490	552	701	777	929	
Rebates in RA (€)		13,064	22,742	55,874	62,803	69,489	65,387	61,769	73,741	
<i>Rituximab</i>	<i>Total acquired</i>									
Rebates (€)	0	48,633	82,676	89,485	95,321	161,332	197,217	217,623	256,074	
Rebates (% Unit)	0	4.20%	7.50%	7.50%	7.50%	13.20%	15.10%	15.0%	17.40%	
Bonus (U)	0	0	0	0	0	0	0	0	0	
Dispensed units (U) in RA	163	136	112	96	107	148	165	186	237	
Rebates in RA (€)	0	6,916	8,760	8,893	9,817	24,616	30,271	34,245	47,876	
<i>Abatacept</i>	<i>Total acquired</i>									
	2009	2010	2011	2012	2013	2014		2015		
	IV(mg)	IV(mg)	IV(mg)	IV(mg)	IV(mg)	IV(mg)	SC (units)	IV(mg)	SC (units)	
Rebates (€)	0	1.567	7.861	22,331	9,399	8,792	984	10,238	9,640	
Rebates (% Unit)	0.00%	2.80%	7.50%	16.40%	11.40%	7.50%	7.50%	7.50%	10.00%	
Bonus (U)	0	0	4,500	4,500	2,500	0	0	0	12	
Dispensed units (U) in RA	58,250	39,250	63,250	76,000	56,750	72,250	60	62,500	416	
Rebates in RA (€)	0	1,567	7,078	19,908	8,603	5,105	984	6,630	9,348	
<i>Tocilizumab</i>	<i>Total acquired</i>									
Rebates (€)	–	6,680	13,971	28,766	73,108	74,536	–	54,698	20,045	
Rebates (% Unit)	–	5.60%	7.50%	9.30%	21.20%	20.90%	–	16.10%	22.10%	
Bonus (U)	–	0	0	0	0	0	–	0	8	
Dispensed units (U) in RA	–	27,200	70,520	101,480	135,040	152,680	–	122,840	368	
Rebates in RA (€)	–	4,285	9,498	17,778	56,081	55,211	–	37,081	20,049	
<i>Abatacept</i>	<i>Total acquired</i>									
	2016		2017		Oral drugs	<i>Total acquired</i>		2017		
	IV(mg)	SC (units)	IV(mg)	SC (units)				Baricitinib	Tofacitinib	
Rebates (€)	9,027	27,504	18,736	31,083	Rebates (€)	580 €		152,203 €		
Rebates (% Unit)	7.50%	19.40%	14.20%	19.20%	Rebates (% Unit)	10.30%		19.80%		
Bonus (U)	0	76	0	80	Bonus (U)	0		0		
Dispensed units (U) in RA	54,500	562	75,750	601	Dispensed units (U) in RA	4		4		
Rebates in RA (€)	5,704	24,228	14,979	25,486	Rebates in RA (€)	0		0		
<i>Tocilizumab</i>	<i>Total acquired</i>									
Rebates (€)	51,188	46,757	60,088	49,436						
Rebates (% Unit)	14.50%	21.30%	17.30%	15.90%						
Bonus (U)	0	72	0	0						
Dispensed units (U) in RA	80,960	843	110,760	1177						
Rebates in RA (€)	23,080	44,040	33,984	47,191						

U: Dispensed or Bonus Units.
RA: Rheumatoid arthritis.

Table 4a
Clinical characteristics of patients according to the optimizations of their treatments.

	2013	P(*)	2017	P(*)
DAS28 optimized group	2.77(0.97)	<.001	2.64(0.96)	<.001
DAS28 not optimized group	4.00(1.25)		3.61(1.34)	
SDAI optimized group	6.11(6.02)	<.001	5.42(4.93)	<.001
SDAI not optimized group	16.96(12.38)		13.06(10.64)	
CRP-C optimized group	3.38 (5.5)	.004	4.70(7.93)	.244
CRP-C not optimized group	9.44 (17.39)		7.65(15.54)	
ESR optimized group	17.62 (11.93)	.553	19.31(14.22)	.197
ESR not optimized group	19.68 (13.93)		22.63(17.47)	

Table 4b
Number of active patients and % patients with optimized therapies per drug.

	2009		2010		2011		2012		2013		2014		2015		2016		2017	
	Active pat	Opt (%)	Active pat	Opt (%)	Active pat	Opt (%)	Active pat	Opt (%)	Active pat	Opt (%)	Active pat	Opt (%)	Active pat	Opt (%)	Active pat	Opt (%)	Active pat	Opt (%)
Etn	87	2.3%	85	3.5%	81	18.5%	83	28.9%	78	59.0%	76	51.3%	78	50.0%	83	57.8%	93	39.8%
Ada	71	0.0%	69	2.9%	64	21.9%	56	37.5%	39	76.9%	36	69.4%	38	52.6%	36	41.7%	27	55.6%
Ctz			3	0.0%	14	0.0%	18	11.1%	26	34.6%	31	29.0%	33	36.4%	43	34.9%	44	29.5%
Goli					2	0.0%	1	0.0%	2	0.0%	4	50.0%	7	14.3%	11	36.4%	13	30.8%
Tcz SC											2	0.0%	16	31.3%	27	25.9%	29	31.0%
Aba SC											2	0.0%	14	0.0%	14	14.3%	13	7.7%
Ifx	63	12.7%	47	14.9%	38	44.7%	32	59.4%	25	60.0%	25	52.0%	20	55.0%	15	73.3%	14	57.1%
Bios Ifx											0	0.0%	4	0.0%	11	0.0%	10	20.0%
Rtx	32	0.0%	36	0.0%	24	0.0%	20	0.0%	22	13.6%	31	9.7%	37	24.3%	42	19.0%	43	34.9%
Tcz IV			10	0.0%	18	0.0%	26	0.0%	33	42.4%	33	54.5%	27	66.7%	18	55.6%	25	32.0%
Aba IV	10	20.0%	3	66.7%	11	9.1%	12	8.3%	6	33.3%	11	18.2%	11	45.5%	10	40.0%	14	28.6%
Oral drugs																	5	0.0%
Total	263	4.6%	253	5.5%	252	18.7%	248	27.0%	231	51.5%	251	44.2%	285	42.1%	310	40.0%	330	35.2%

Data are expressed as mean (SD) for continuous variables and frequencies (percentage) for categorical variables.

DAS28: Disease Activity Score 28; SDAI: Simplified Disease Activity Index.

CRP-C: C-Reactive Protein; ESR Erithrocite Sedimentation Rate.

Statistical signification $P < .05$; (*) T-Test Mann–Whitney U.

Active pat: number of active patients per drug.

Opt (%): Percentage of patients with optimized therapies per drug.

Etn: Etanercept; Ada: Adalimumab; Ctz: Certolizumab; Goli: Golimumab; Tcz: Tocilizumab; Aba: Abatacept; Ifx: Infliximab; Bios Ifx: Biosimilar Ifx; Rtx: Rituximab; Oral drugs: Baricitinib and Tofacitinib.




Fig. 2. Proportion of active patients with optimized regimes.

conducted from 2013 to 2015, concluded that Ifx (€10,717) had the lowest cost per patient per year under the established practice, followed by Etn (€11,015) and Ada (€11,977). Our study differs in that the costs of Ifx, Etn, and Ada were lower (41.3%, 28.5%, and 41.7%, respectively), compared with the aforementioned study in 2015. Mariatena et al.,²¹ in a study conducted in 2013, concluded that Ifx (€10,073) had the lowest cost per patient per year under the established practice, followed by Toci (€10,798), Eta (€11,056),

and Ada (€11,512). Our study differs in that the costs of Ifx, Toci, Etn, and Ada were lower (46.1%, 22.3%, 33.1% and 37.0%, respectively), compared with the aforementioned study in 2013. Toci, Eta and Ada doses in the first study were optimized empirically and they were reduced a 13.3%, 6.9% and 10.7% for Toci, Eta and Ada, respectively. Ramírez-Herraz et al.²² concluded that mean doses used were significantly lower with Eta than with Ada and Ifx and they used 81.0%, 93.02% and 135.73% of recommended dose

Table 5
Calculation of different factors that have an impact on costs in 2017.

Annus Drugs	Theoretical Unit per annus	Theoretical cost (Unit or mg)	Average Dispensed pat	Theoretical Annual cost € (A)	Annual Cost (€)(B)	Saved Cost (€)(A-B)	Rebates, Discount €(C)	Saved Optimized Regimes €(A-B-C)
RA 2017								
Certolizumab	30	442	44.48	589.804,80	335.283	254.521,80	73.441,00	181.080,80
Etanercept	2.600,00	4.28	86.16	958.788,48	579.680	379.108,48	104.113,00	274.995,48
Adalimumab	26	480,54	30.73	383.941,85	215.512	168.429,85	46.500,00	121.929,85
Rituximab	8	1.261,77	29.51	297.878,66	242.484	55.394,66	47.876,00	7.518,66
Abatacept SC	52	218,59	12.86	146.175,50	102.692	43.483,50	25.486,00	17.997,50
Abatacept IV	9.100,00	1.37	10.21	127.288,07	90.261	37.027,07	14.979,00	22.048,07
Infliximab + BIOSIM	1.499,40	4.18	27.68	173.484,18	92.414	81.070,18	43.842,00	37.228,18
Tocilizumab IV	7.280,00	1.74	20.92	264.997,82	158.076	106.921,82	33.984,00	72.937,82
Tocilizumab SC	52	243,91	28.9	366.547,95	240.921	125.626,95	47.191,00	78.435,95
Golimumab	13	921,63	11.38	136.345,94	96.171	40.174,94	20.119,00	20.055,94
Baricitinib (envase)	13	706,06	0.33	3.029,00	2.508	521	580	-59
Tofacitinib (envase)	13	706,06	0.42	3.855,09	7.600	-3.744,91	424	-4.168,91
Total 2017			303.58	3.452.137,34	2.163.602	1.288.535,34	458.535,00	830.000,34

Theoretical annual cost: Theoretical unit per annus × Theoretical cost (unit or mg) × Average-dispensed-patient.

Average dispensed pat: average-dispensed-patient.

Saved cost (€): Theoretical annual cost – Annual cost.

Saved optimized regimes: Theoretical annual cost – Annual cost – Rebates and discounts.

Table 6
Quantification of influential factor that affect on treatment costs in rheumatoid arthritis.

Rheumatoid arthritis	2009	%	2011	%	2013	%	2015	%	2017	%
Annual cost (€) (AC)	10.798,00 €	95.00%	9.547,00	77.51%	7.491,00	59.55%	7.242,00	61.23%	7.116,00	61.29%
Theoretical annual cost (€)(TAC)	11.367 €	100.00%	12.317 €	100.00%	12.579 €	100.00%	11.828 €	100.00%	11.610 €	100.00%
Difference (€): (TAC) – (AC)	568,51 €	5.00%	2.769,78 €	22.49%	5.087,96 €	40.45%	4.585,65 €	38.77%	4.493,95 €	38.71%
Total saved cost (€):	132.268,16 €	0.58%	574.193,00	22.49%	1.062.529,00	40.45%	1.049.073,00	38.77%	1.288.535,34	38.71%
* Rebates + bonus + offitil discount (€)	17.193,50 €	0.08%	254.837,19	9.98%	264.622,48	10.07%	318.262,83	11.76%	458.535,00	13.77%
- Royal Decret Law (€)	0.00 €	0.00%	191.500,79	7.50%	197.016,76	7.50%	202.938,51	7.50%	249.666,02	7.50%
- Negotiated Rebates and Bonus (€)	17.193,50	0.08%	63.336,40	2.48%	67.605,72	2.57%	115.324,32	4.26%	208.868,98	6.27%
* Saved by optimized regimes (€)	115.074,00 €	0.50%	322.882,00	12.51%	797.907,00	30.37%	730.810,00	27.01%	830.000,34	24.93%

for Eta, Ada and lfx, respectively. In this study, BD were optimized empirically, controlling for disease activity. Thus patient-year cost in 2011 were €9594, €11,962 and €10,094 for Eta, Ada and lfx, respectively. Our study differs in that the costs of Ada and lfx were lower (15.4%, 25.6% respectively), and costs of Eta was higher (3.4%). Finally, Ivorra et al.²³ published annual costs per patient and per drug referred to 2013 and our data for the same period showed that these therapies were cheaper 54.3% for lfx, 43.6% in Ada, 40.1% in Tcz, 37.6% in Eta, 36.0% in Aba IV, 32.1% in Ctz and 19.8% in Goli, that reported in the aforementioned study.

Although in most of these studies the treatments were empirically optimized, our results showed marked differences in RA. This could be explained by the fact that the monitoring of drugs (Etn, lfx, Ada, Toci) helps the clinician to optimize treatments earlier, with greater safety, and lower doses and wider dosing intervals regarding empirical optimization.

According to the EULAR recommendations,⁷ tapering of a biological drug can be considered in patients that achieve persistent remission. REDOSER project established criteria for reducing doses of biological therapies for RA, both extending the dosing interval and/or reducing the dose. In addition, serum drug levels and ADAs in serum, when available, can help to clinicians to optimize biological therapy and the clinical monitoring.²⁴

We observed that patients with optimized regimes increased from 12 (4.6%) to 116 (35.2%) patients (2009–2017). Monitoring of lfx, Etn and Ada using serum levels is used by clinicians in clinical practice in our center from 2011^{14–16}; serum levels for monitoring Toci began in 2014 and Goli and Rtx began in 2015, and were available in usual practice in 2017, and for their optimization, rheumatologists have stablished clinical protocols.

Our results show that optimization of biological therapies leads to a marked costs reduction. Moreover, other authors proved that

dosing regimen optimization of biologicals does not mean an increase in disease activity parameters, no differences with patients under full dose regimens were found.^{16,25}

In parallel with the beginning of the optimization of treatments, costs decreased. Ada and lfx annual costs decreased mainly in 2011 and 2012 and Etn in 2013.

When analyzing savings related to therapy optimizations, we detected that the main factor contributing to these savings was optimization by drug serum levels monitorization that were around 80%, respect saving related to empirically optimizations, for analyzed years as we described in result section.

The majority of drugs that contributed to cost savings by optimization were Ada, Etn, lfx and Tcz group over Goli and Ctz, coinciding with the percentage of optimized regimes for these drugs, in which Goli and Ctz were optimized in a lower percentage than first group probably they joined later.

The presence in the market of many drugs for a pathology produces an economic competition.²⁶ However, bonus units and discounts can then reduce the expenditure on medicines. In our hospital, we have observed that introduction of Goli, Ctz, and Aba or Tcz SC was accompanied by significant invoice discounts of between 15.9% and 37% in different years; and bonus units gradually rose during the study period.

It is known that when a biosimilar is released there is an increased access and a lower health cost burden. According to the law in Spain, when a biosimilar is marketed the original have to decrease its price to the same level of the biosimilar.^{27,28} Over the study period the European Medicines Agency approved biosimilars of lfx and Etn in 2013 and 2015 respectively, which led to an increase in discounts for lfx and Eta.

Original lfx rebate in our study (24.6%) are in line with the reduction in the price of infliximab published articles,²⁹ however biosimilar lfx retabe obtained (43.1%) exceed published data.³⁰

Taking together all factors influencing annual RA cost per patient we observed that when the annual cost decreased slightly, increased the number of treated patients and the total saved costs. Our results show that the greatest saving contributions were biological therapy were optimizations, followed by official discounts and negotiated rebates.

Taking into account our results future strategies leading toward the implementation of therapeutic drug monitoring based on scientific evidence³¹ should be promoted in order to reduce costs and maintaining disease control at the same time.

There were several study limitations. Farmatools does not provide definitive reports of economic and clinical results in order to make a posterior statistical analysis. We have to do a data treatment before use them. Moreover, the annual theoretical cost of lfx could be overestimated because we considered an estimated average weight of 70 kg for all patients treated. Moreover, the saved by optimized regimes could be overestimated because units not dispensed by the possible lack of adherence to treatment are not included. Finally, costs from 2009 to 2017 were not adjusted.

The most important strength of our study is the very long analysis period and the large sample size, which allowed us to analyze and to quantify influential factors in decreasing cost per patient and to prove that optimization was the strategy that most influenced this decline.

Also, *annual cost per average-dispensed-patient* allows us to compare our data with other hospitals in Spain.

Conclusion

Our study proves that the greatest contribution to economic savings in biological therapy in rheumatoid arthritis was biological therapy optimization by monitoring drug and ADA serum levels when comparing with official discounts, negotiated rebates.

Financial disclosure

No financial support.

Conflict of interest

No conflicts of interest have been declared.

References

- Gibofsky A. Epidemiology, pathophysiology, and diagnosis of rheumatoid arthritis: a synopsis. *Am J Manag Care*. 2014;20:S128–35.
- Kvien TK. Epidemiology and burden of illness of rheumatoid arthritis. *Pharmacoeconomics*. 2004;22:1–12.
- Carmona L, Villaverde V, Hernández-García C, Ballina J, Gabriel R, Laffon A, et al. The prevalence of rheumatoid arthritis in the general population of Spain. *Rheumatol Oxf Engl*. 2002;41:88–95.
- Gissel C, Götz G, Repp H. Cost-effectiveness of adalimumab for rheumatoid arthritis in Germany. *Z Rheumatol*. 2016;75:1006–15.
- Singh JA, Saag KG, Bridges SL, Akl EA, Bannuru RR, Sullivan MC, et al. 2015 American College of Rheumatology Guideline for the treatment of rheumatoid arthritis. *Arthritis Rheumatol Hoboken NJ*. 2016;68:1–26.
- Sanmartí R, García-Rodríguez S, Álvaro-Gracia JM, Andreu JL, Balsa A, Cáliz R, et al. 2014 update of the consensus statement of the Spanish society of rheumatology on the use of biological therapies in rheumatoid arthritis. *Reumatol Clín Engl Ed*. 2015;11:279–94.
- Smolen JS, Landewé R, Bijlsma J, Burmester G, Chatzidionysiu K, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. *Ann Rheum Dis*. 2017;76:960–77.
- Smolen JS, Breedveld FC, Burmester GR, Bykerk V, Dougados M, Emery P, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. *Ann Rheum Dis*. 2016;75:3–15.
- Smolen JS, Landewé R, Breedveld FC, Buch M, Burmester G, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. *Ann Rheum Dis*. 2014;73:492–509.
- Kuek A, Hazleman BL, Ostör AJK. Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution. *Postgrad Med J*. 2007;83:251–60.
- Tanaka Y. Next stage of RA treatment: is TNF inhibitor-free remission a possible treatment goal? *Ann Rheum Dis*. 2013;72, ii124–7.
- Microsoft Word – Informe técnico ANTI-TNF – reumatologia.pdf (Internet). Available from: <http://sescam.castillalamancha.es/sites/sescam.castillalamancha.es/files/documentos/farmacia/reumatologia.pdf> [cited 21.06.17].
- L GQ, Coral-Alvarado P. Economic Impact of Rheumatic Diseases. *Chall Rheumatol* (Internet). 2011. Available from: <http://www.intechopen.com/books/challenges-in-rheumatology/economic-impact-of-rheumatic-diseases> [cited 5.03.18].
- Plasencia C, Pascual-Salcedo D, García-Carazo S, Lojo L, Nuño L, Villalba A, et al. The immunogenicity to the first anti-TNF therapy determines the outcome of switching to a second anti-TNF therapy in spondyloarthritis patients. *Arthritis Res Ther*. 2013;15:R79.
- González MAF, Moreno FR, Hugo AV, Plasencia C, Salcedo DP, Pinto PH, et al. Anti-tnf dose and anti-drug antibody levels in rheumatic and psoriasis patients: Economic repercussion. *Eur J Clin Pharm Aten Farm*. 2015;17:4.
- González-Fernández M, Villamañán E, Jiménez-Nácher I, Moreno F, Plasencia C, Gaya F, et al. Cost evolution of biological agents for the treatment of spondyloarthritis in a tertiary hospital: influential factors in price. *Int J Clin Pharm*. 2018;40:1528–38. <http://dx.doi.org/10.1007/s11096-018-0703-z>.
- Balsa A. ¿Cómo se evalúa una respuesta inadecuada en un paciente con artritis reumatoide en la práctica clínica? *Reumatol Clín*. 2007;3:38–44.
- Real Decreto Legislativo 3/2011, de 14 de noviembre, por el que se aprueba el texto refundido de la Ley de Contratos del Sector Público. BOE-A-2011-17887 (Internet). Available from: <https://www.boe.es/buscar/act.php?id=BOE-A-2011-17887> [cited 3.03.17].
- Real Decreto-ley 4/2010, de 26 de marzo, de racionalización del gasto farmacéutico con cargo al Sistema Nacional de Salud. Jefatura del Estado Referencia: BOE-A-2010-5030 (Internet). Available from: <https://www.boe.es/buscar/doc.php?id=BOE-A-2010-5030> [cited 2.07.17].
- Gómez-De Rueda F. Análisis y evaluación del coste del tratamiento anti-TNFalfa en artritis reumatoide y espondilitis. *J Negat No Posit Results*. 2017:233–9.
- Estudio del coste de las terapias biológicas en patologías reumáticas según práctica clínica de un hospital (Internet). Revista de la OFIL. 2017. Available from: <http://www.revistadelaofil.org/estudio-del-coste-las-terapias-biologicas-patologias-reumaticas-segun-practica-clinica-hospital/> [cited 8.07.17].
- Ramírez-Herráiz E, Escudero-Vilaplana V, Alañón-Plaza E, Trovato-López N, Herranz-Alonso A, Morell-Baladrón A, et al. Efficiency of adalimumab, etanercept and infliximab in rheumatoid arthritis patients: dosing patterns and effectiveness in daily clinical practice. *Clin Exp Rheumatol*. 2013;31:559–65.
- Ivorra R, Andrés J, Ivorra J, Monte-Boquet E, Canal C, Oyagüez I, et al. Análisis de costes de la utilización de fármacos biológicos para la artritis reumatoide en primera línea de tratamiento tras respuesta inadecuada a metotrexato en función del peso de los pacientes. *Reumatol Clín*. 2016;12:123–9.
- REDOSER project: optimising biological therapy dose for rheumatoid arthritis and spondyloarthritis patients – ScienceDirect (Internet). Available from: <https://www.sciencedirect.com/science/article/pii/S2405844017310150> [cited 25.07.18].
- Pascual-Salcedo D, Plasencia C, Ramiro S, Nuño L, Bonilla G, Nagore D, et al. Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis. *Rheumatol Oxf Engl*. 2011;5:52–1445.
- Westhovens R, Anemans L. Costs of drugs for treatment of rheumatic diseases. *RMD Open*. 2016;2:e000259.
- Guideline on similar biological medicinal products. 2014. (Internet). Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/10/WC500176768.pdf.
- Real Decreto 177/2014, de 21 de marzo, por el que se regula el sistema de precios de referencia y de agrupaciones homogéneas de medicamentos en el Sistema Nacional de Salud, y determinados sistemas de información en materia de financiación y precios de los medicamentos y productos sanitarios (Internet). Noticias Jurídicas. Available from: http://noticias.juridicas.com/base_datos/Fiscal/526168-rd-177-2014-de-21-mar-sistema-de-precios-de-referencia-y-de-agrupaciones.html [cited 22.07.18].
- Rencz F, Péntek M, Bortlik M, Zagorowicz E, Hlavaty T, Śliwczynski A, et al. Biological therapy in inflammatory bowel diseases: access in Central and Eastern Europe. *World J Gastroenterol WJG*. 2015;21:37–1728.
- Farfan-Portet M-I, Gerkens S, Lepage-Nefkens I, Vinck I, Hulstaert F. Are biosimilars the next tool to guarantee cost-containment for pharmaceutical expenditures? *Eur J Health Econ HEPAC Health Econ Prev Care*. 2014;15:223–8.
- Paintaud G, Passot C, Ternant D, Bertolotto A, Bejan-Angoulvant T, Pascual-Salcedo D, et al. Rationale for therapeutic drug monitoring of biopharmaceuticals in inflammatory diseases. *Ther Drug Monit*. 2017;39:339–43.